A CaCO3-based synergistic immunotherapy strategy for treating primary and distal tumors†
Abstract
Low response rate limits the widespread application of cancer immunotherapy. To improve the response rate of immunotherapy, a CaCO3-based composite nanomaterial was developed to induce immunogenic cell death for enhancing immunotherapy against 4T1 primary and distal tumors.